BRISTOL MYERS SQUIBB
- Country
- 🇫🇷France
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
A Study to Describe the Persistence With Ozanimod Treatment in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants
- Conditions
- First Posted Date
- 2023-04-13
- Last Posted Date
- 2023-12-05
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 200
- Registration Number
- NCT05811416
- Locations
- 🇪🇸
Local Institution - 0001, Barcelona, Spain
A Study to Evaluate the Drug Levels, Safety, and Tolerability of BMS-986278 in Healthy Chinese Participants
- First Posted Date
- 2023-04-10
- Last Posted Date
- 2023-09-18
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 24
- Registration Number
- NCT05805904
- Locations
- 🇨🇳
Local Institution - 0001, Shanghai, China
A Study to Evaluate the Safety, Tolerability, and Drug Levels of Danicamtiv in Healthy Japanese and Caucasian Participants
- First Posted Date
- 2023-04-10
- Last Posted Date
- 2024-05-23
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 33
- Registration Number
- NCT05806359
- Locations
- 🇺🇸
Anaheim Clinical Trials, Anaheim, California, United States
A Study to Evaluate Nivolumab in the Treatment of Early Stage Esophageal or Gastroesophageal Cancer
- Conditions
- First Posted Date
- 2023-03-23
- Last Posted Date
- 2024-08-26
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 314
- Registration Number
- NCT05780736
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Pacific Central Coast Health Centers - San Luis Obispo Oncology and Hematology Health Center, San Luis Obispo, California, United States
🇺🇸Mission Cancer Center, Santa Maria, California, United States
A Study to Evaluate Nivolumab in Japanese Participants With Muscle-invasive Urothelial Carcinoma
- Conditions
- First Posted Date
- 2023-03-22
- Last Posted Date
- 2023-03-22
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 400
- Registration Number
- NCT05779592
- Locations
- 🇯🇵
Local Institution, City, State, Japan
A Study to Evaluate the Safety, Tolerability and Drug Levels of BMS-986447 in Healthy Participants
- First Posted Date
- 2023-03-09
- Last Posted Date
- 2024-04-05
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 32
- Registration Number
- NCT05760937
- Locations
- 🇺🇸
Local Institution - 0001, Anaheim, California, United States
A Real-world Observational Study to Compare Effectiveness of Deucravacitinib Vs Apremilast in Adults With Plaque Psoriasis
- First Posted Date
- 2023-02-27
- Last Posted Date
- 2024-07-23
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 1500
- Registration Number
- NCT05744466
- Locations
- 🇺🇸
Local Institution, Waltham, Massachusetts, United States
A Study to Evaluate Treatment Preferences for Japanese Participants With Muscle-invasive Urothelial Carcinoma of the Bladder
- Conditions
- First Posted Date
- 2023-02-24
- Last Posted Date
- 2024-01-08
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 115
- Registration Number
- NCT05742867
- Locations
- 🇺🇸
Local Institution - 0001, Morrisville, North Carolina, United States
A Study to Evaluate Effectiveness and Safety of BMS-986322 in Participants With Moderate-to-Severe Psoriasis
- First Posted Date
- 2023-02-16
- Last Posted Date
- 2024-06-25
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 120
- Registration Number
- NCT05730725
- Locations
- 🇺🇸
Local Institution - 0008, Cleveland, Ohio, United States
🇺🇸Local Institution - 0001, Los Angeles, California, United States
🇺🇸Local Institution - 0016, Los Angeles, California, United States
A Study to Evaluate the Effects of Mavacamten in Healthy Participants
- First Posted Date
- 2023-02-09
- Last Posted Date
- 2023-10-12
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 84
- Registration Number
- NCT05719805
- Locations
- 🇺🇸
Local Institution - 0002, Saint Paul, Minnesota, United States
🇺🇸Local Institution - 0001, Miami, Florida, United States